Is an Oral Neuroleptic Suitable for Continuing Drug Treatment in Schizophrenia? by Dr D C Watt (St John's Hospital, Aylesbury, Buckinghamshire) Continuing treatments for schizophrenia have, during the last decade, been predominantly administered by injection. This was due to the fact that a workable slow-release compound which would produce a sustained effect was only suitable in the first place for administration by injection. However, the injection itself has had an aura cast around it and it has often been believed that there are special advantages in the mere fact that a compound is administered in this way. There have always been considerable doubts about this belief, some of which have been touched on in Dr Lader's presentation. The assumptions on which this belief depends have not been thoroughly explored nor vigorously tested.
When pimozide was first put on the market and offered as an oral neuroleptic with a sustained action, the opportunity was taken by the Clinical Trials Sub-Committee of the Medical Research Council to plan a trial, in which the 2 methods of administration would be assessed, at St John's Hospital in Buckinghamshire. The trial took place between 1972 and the beginning of 1977. The work was mainly undertaken by Dr Ian Falloon with the assistance of Professor Michael Shepherd, the present author and a team of social workers.
The choice of St John's Hospital was not accidental. It is situated in the middle of the county of Buckinghamshire, the main part of which forms its catchment area, which, compared with the majority of mental hospitals, is particularly well-marked. The hospital has had the same catchment area for over 100 years and the population is stable because of a relatively low emigration from the county. It has already received attention because of such advantages for this kind of study, which to some extent determined its choice for this trial (Shepherd 1957 , Shepherd et al. 1961 ). Dr D C Watt 1974) was administered. This is essentially a check list of symptoms together with instructions on how to elicit them and the criteria for considering them to be present in the patient. Thus, it indicates the standard ingredients for each particular diagnosis. In our case we were not concerned with the whole range of diagnosis but simply with confirming or refuting the diagnosis of schizophrenia and confirming the absence of other diagnoses. We thus determined first whether or not schizophrenic symptomatology was present and, secondly, whether it was present in the way and to the degree required to meet the PSE criteria for the diagnosis of schizophrenia. The diagnosis was made at 2 grades: either that schizophrenia was definitely present or that it was probably present. Both categories were considered suitable for the trial.
Not all of these 136 subjects were able to enter the trial because the consent of the consultant under whose care the patient had been admitted to hospital and also the consent of the patient was required. It is interesting, in view of the outcome of the trial, that consultants frequently objected that only an injected medication was suitable for continuation treatment in particular cases. Altogether, 44 of the 136 patients who had been examined entered the trial.
Trial Design After the diagnosis of schizophrenia had been made and it was agreed that the patient was suitable for the trial, a random allocation was made to treatment either by oral or by injected medication. In order that assessment should be blind, all patients had both an oral and an injected preparation. Those patients allocated to ,oral medication (pimozide) had, in addition, an inert injection, while those allocated to injected medication (fluphenazine) had also an inert oral preparation. The 2 groups of patients were compared on a number of variables to ensure that the 2 populations were similar, as is fully described elsewhere (Falloon et al. 1978a) .
In order to check that medications were taken, both sets of tablets (active and inert) had riboflavine added. Riboflavine is quickly excreted in urine and a simple test shows fluorescence if it is present (Jones & Letemendia 1966) .
Patients were permitted sedative, anti-Parkinsonian and antidepressant medication but during the period of the trial could not have any other tranquillizer or neuroleptic.
Trial medication was established while the patient was in hospital and the patient entered the trial on discharge from hospital. He was then referred to the schizophrenic follow-up clinic of his area. The clinics are organized by a community psychiatric nurse, who administered the injections and supplied the tablets for the trial. They are held in general hospitals in the main towns of Buckinghamshire at the end of the working day and at a time when there is also a psychiatric out-patient clinic. Thus it is convenient for the nurse to refer patients for a psychiatrist's opinion or for any other service that may be required.
The period of follow-up was 1 year and during this time there were 2 kinds of assessment, clinical and social, each administered twice. First, there was an assessment 1 month after discharge when it was hoped that patients would be settled at home and established on the drug regime at the clinic. The general practitioner was informed that the patient was in the trial and what the medication alternatives were. The second assessment was done either at the end of a year or, if necessary, at the time of relapse. For this purpose relapse was considered to be a disabling increase of schizophrenic symptoms that required a change of medication.
Clinical assessment was by psychiatric interview in which an abbreviated form of the Present State Examination was administered to cover schizophrenic and depressive symptomatology. A rated check-list of side-effects was completed at the same time. Social functioning was assessed by the MRC Social Performance Schedule (Stevens 1972) administered by a social worker during a home visit. Both social and clinical assessments were carried out at 1 month and 1 year after discharge or at relapse and these are described ftlly in another publication (Falloon et al. 1978a) .
Results
At the end of the year, 24 % of patients on oral medication and 40 % of those on injected medication had relapsed. The difference is not significant. There was also no significant difference in rate of relapse between the 2 groups of patients. It is of interest that 4 patients were found to have refused medication at the time of relapse. Two of these were on the active oral preparation and 2 of them on the active injection. Apart from these individuals, it was concluded from the checks made (detection of riboflavine in urine and tablet count) that most patients had taken an adequate dosage of medication, although 50% showed evidence of irregular drug taking. Of these, 55 % were on active injections and 45 % on active oral medication.
Among 20 patients entering a second stage of the trial, in which oral preparations only were used, there were 4 relapses; 3 among patients on placebo and 1 among those on pimozide. The numbers are too small for a significant result and any indication that pimozide may have an effect in preventing relapse at a later stage of follow-up needs further investigation.
Conclusions
It seems from this trial that an oral medication can be as effective therapeutically as an injected preparation. It also seems that the oral route of administration ensures delivery and ingestion of the medication as effectively as injection. It is important to note that the advantages in the oral preparation were as much in the social as in the clinical field (Falloon et al. 1978b) .
These results are also apparently supported by those of a trial conducted on similar lines in America, which also compared 2 methods of administration. This multi-centre trial was sponsored and organized by the Psychopharmacology Branch of the National Institute of Mental Health. It included about 200 patients and compared an oral phenothiazine with an injected long-acting neuroleptic. As in the Medical Research Council trial, each subject was given an injection and an oral preparation, one of which was placebo and one active. The results showed that there was no difference in the efficacy of the 2 preparations.
From these 2 studies it is quite clear that, so long as there are sufficient supporting services to ensure adequate ingestion, an oral preparation is as effective as an equipotent injection. In addition, an organization similar to that which is now set up to administer injections can provide the kind of back-up that is needed for administering and ensuring the effectiveness of an oral preparation. It is quite possible that some of the advantages claimed for an injected preparation are more readily attributable to the organization that is required to administer it.
One serious consideration arising from this study is why in psychiatry it takes so long to obtain answers to questions of this type. Longacting neuroleptics have been available for more than 10 years. They are not without their disadvantages (as everybody using them knows) and it seems that a question of this nature could have been answered within 4-5 years of their introduction. This is a question to which all psychiatrists using these drugs and other kinds of treatment in psychiatry, must address themselves. Dr Watt said that the significance ofthe differences was tested in a variety of ways and it was nonsignificant to the satisfaction of the Medical Research Council's statisticians. In their view, the trial had been of adequate length.
Dr J M Tarsh (Salford) said that the attractive feature of an injectible preparation was that it required only a single administration by the nurse, whereas with patients on oral medication one had to hope that either they or their relatives would send to the GP's receptionist so that a repeat prescription could be given. When the nurses in the trial followed the patients in a hospital clinic, the injections and pills were equally good. However, he wondered what would have happened had the injections been given by the nurse and the pills taken in the way that they are usually taken (or not taken). A corollary to the question was whether, if schizophrenics were to be maintained in the community, either taking pills or having injections, they would have to be constantly followed up by community nurses in hospital clinics or health centres under the control of the psychiatrists in the catchment area.
Dr Watt said that there were 2 aspects to this question. Firstly it was not only consultants who refused permission for patients to come into the trial. Patients themselves sometimes refused. Indeed they more often refused injections than they refused tablets. On the other aspect, he did anticipate that as long as treatment was required, follow-up by community nurses would be necessary. If the patient did not come to receive medication, the nurse would send a reminder and if that was not effective would visit the patient's home. Indeed, some patients would have difficulty in getting to the clinic, a mother with small children and no transport, for example. He believed the study to indicate that this kind of basic back-up service was required for the follow-up of schizophrenic patients. It did contribute very largely to maintaining the medication and hence to the results that were obtained.
